Preoperative serum magnesium level as a prognostic and predictive biomarker in locally advanced gastric cancer patients receiving neoadjuvant immunochemotherapy

术前血清镁水平作为接受新辅助免疫化疗的局部晚期胃癌患者的预后和预测生物标志物

阅读:1

Abstract

BACKGROUND: The global multicenter phase III MATTERHORN trial further validated the scientific rationale and clinical value of our earlier research, demonstrating that the combination therapy significantly improved patient survival outcomes and provided critical evidence for optimizing gastric cancer treatment strategies worldwide. Nevertheless, despite the overall effectiveness of neoadjuvant immunochemotherapy (NICT), approximately half of the patients did not achieve optimal therapeutic responses. Moreover, only a few clinically useful biomarkers can predict the treatment outcomes. The relationship between pre-treatment serum electrolyte levels and treatment outcomes in patients with locally advanced gastric cancer (LAGC) after NICT remains unclear. METHODS: A retrospective analysis was conducted on clinical data from 112 patients with LAGC who underwent radical surgery after NICT between 2020 and 2024. Serum electrolyte levels were measured prior to NICT. The associations between serum electrolyte levels and overall survival (OS) and disease-free survival (DFS) were evaluated. RESULTS: In the Kaplan-Meier survival analysis of pre-treatment serum electrolytes, only sodium showed a significant association; however, it was not an independent prognostic factor, according to the Cox regression analysis. Low pre-treatment serum magnesium levels were significantly associated with poorer OS (HR = 21.48, P < 0.001) and DFS (HR = 8.730, P < 0.001). Multivariate Cox regression analysis confirmed that low serum magnesium was an independent prognostic factor for both OS (HR = 0.232, P = 0.007) and DFS (HR = 0.274, P = 0.004). Low magnesium levels were more prevalent in patients with signet ring cell carcinoma or positive perineural invasion. Furthermore, low serum magnesium levels were associated with a poor rate of major pathological response (P < 0.0001). CONCLUSION: Pre-treatment serum magnesium levels are independent prognostic factors and potential biomarkers in patients with LAGC undergoing NICT. However, prospective studies are required to validate these findings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。